Details

Autor(en) / Beteiligte

• Gaab, Christine
• Adolph, Jonas E
• Tippelt, Stephan
• Mikasch, Ruth
• Obrecht, Denise
• Mynarek, Martin
• Rutkowski, Stefan
• Pfister, Stefan M
• Milde, Till
• Witt, Olaf
• Bison, Brigitte
• Warmuth-Metz, Monika
• Kortmann, Rolf-Dieter
• Dietzsch, Stefan
• Pietsch, Torsten
• Timmermann, Beate
• Sträter, Ronald
• Bode, Udo
• Faldum, Andreas
• Kwiecien, Robert
• Fleischhack, Gudrun

Titel

Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study

Ist Teil von

• Cancers, 2022-01, Vol.14 (3), p.471

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2022

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Recurrent medulloblastomas are associated with survival rates <10%. Adequate multimodal therapy is being discussed as having a major impact on survival. In this study, 93 patients with recurrent medulloblastoma treated in the German P-HIT-REZ 2005 Study were analyzed for survival (PFS, OS) dependent on patient, disease, and treatment characteristics. The median age at the first recurrence was 10.1 years (IQR: 6.9-16.1). Median PFS and OS, at first recurrence, were 7.9 months (CI: 5.7-10.0) and 18.5 months (CI: 13.6-23.5), respectively. Early relapses/progressions (<18 months, = 30/93) found mainly in molecular subgroup 3 were associated with markedly worse median PFS (HR: 2.34) and OS (HR: 3.26) in regression analyses. A significant survival advantage was found for the use of volume-reducing surgery as well as radiotherapy. Intravenous chemotherapy with carboplatin and etoposide (ivCHT, = 28/93) showed improved PFS and OS data and the best objective response rate (ORR) was 66.7% compared to oral temozolomide (oCHT, = 47/93) which was 34.8%. Intraventricular ( = 43) as well as high-dose chemotherapy ( = 17) at first relapse was not related to a significant survival benefit. Although the results are limited due to a non-randomized study design, they may serve as a basis for future treatment decisions in order to improve the patients' survival.